SAN DIEGO, March 2 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. , a biopharmaceutical company developing and commercializing recombinant human enzymes, today announced that it will present at the Cowen & Co. 26th Annual Health Care Conference to be held at the Boston Marriott Copley Place Hotel, on March 6-9, 2006.
Jonathan Lim, MD, Halozyme's President and Chief Executive Officer, will present on Thursday, March 9, at 10:30 AM Eastern Time (7:30 AM Pacific Time) and will discuss the Company's strategic initiatives, product pipeline and market opportunities.
Interested parties can access a live audio web cast of the presentation at www.halozyme.com. A replay of the presentation will be available for 14 days.
About Halozyme Therapeutics, Inc.
Halozyme is a biopharmaceutical company developing and commercializing recombinant human enzymes for the infertility, palliative care, and oncology markets. The company's portfolio of products is based on intellectual property covering the family of human enzymes known as hyaluronidases. Halozyme's recombinant human enzymes may replace current animal slaughterhouse-derived extracts that carry potential risks of animal pathogen transmission and immunogenicity. The company has received FDA approval for two products: Cumulase(TM), the first and only recombinant human hyaluronidase for cumulus removal in the IVF process; and Hylenex(TM), for use as an adjuvant to increase the absorption and dispersion of other injected drugs. The versatility of the first enzyme, rHuPH20, enables Halozyme to develop the product as a medical device, drug enhancement agent, and therapeutic drug.
Halozyme Contact Investor Relations Contacts David A. Ramsay Zachary Bryant Chief Financial Officer Lippert/Heilshorn & Associates (858) 794-8889 (310) 691-7100 dramsay@halozyme.comzbryant@lhai.com
Halozyme Therapeutics, Inc.CONTACT: David A. Ramsay, Chief Financial Officer of HalozymeTherapeutics, Inc., +1-858-794-8889, dramsay@halozyme.com; or InvestorRelations, Zachary Bryant of Lippert/Heilshorn & Associates,+1-310-691-7100, zbryant@lhai.com, for Halozyme Therapeutics, Inc.
Web site: http://www.halozyme.com//
